User profiles for Daan G Knapen
Daan KnapenUMCG Verified email at umcg.nl Cited by 134 |
[HTML][HTML] Potential, limitations and risks of cannabis-derived products in cancer treatment
…, PW Lebbink, FJH Hoogwater, DG Knapen… - Cancers, 2023 - mdpi.com
Simple Summary It is easy to find success stories on the internet of patients with cancer who
seem to benefit from using cannabis products. However, scientific substantiation is usually …
seem to benefit from using cannabis products. However, scientific substantiation is usually …
[HTML][HTML] Molecular imaging to support cancer immunotherapy
PP van de Donk, SF Oosting, DG Knapen… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology.
These monoclonal antibody-based therapies allow the immune system to recognize and …
These monoclonal antibody-based therapies allow the immune system to recognize and …
[HTML][HTML] Opportunities on the horizon for the management of early colon cancer
DG Knapen, JJ de Haan, RSN Fehrmann… - Critical Reviews in …, 2023 - Elsevier
There is a clear unmet need to improve early colon cancer management. This review
encompasses the current systemic treatment landscape and summarises novel and pivotal trials. …
encompasses the current systemic treatment landscape and summarises novel and pivotal trials. …
[HTML][HTML] Which patients are prone to undergo disproportionate recurrent CT imaging and should we worry?
TC Kwee, H Dijkstra, DG Knapen, EGE de Vries… - European Journal of …, 2020 - Elsevier
Purpose To identify the spectrum of patients who undergo disproportionate recurrent computed
tomography (CT) imaging, and to explore the cumulative effects of radiation exposure …
tomography (CT) imaging, and to explore the cumulative effects of radiation exposure …
[HTML][HTML] Urine as sample type for molecular diagnosis of natural yellow fever virus infections
…, M Koopmans, DG Knapen… - Journal of clinical …, 2017 - Am Soc Microbiol
Department of Viroscience, Erasmus MC, Rotterdam, the Netherlandsa; Department of
Medical Microbiology and Infection Prevention, University of Groningen, University Medical …
Medical Microbiology and Infection Prevention, University of Groningen, University Medical …
89Zr-3, 2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin-targeted 227Th-conjugate therapy in mice
The mesothelin (MSLN)-targeted 227 Th conjugate is a novel α-therapy developed to treat
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
[PDF][PDF] A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific …
… Johann S de Bono1, Hendrik-Tobias Arkenau2, Eelke H Gort3, Lot A Devriese3, Elisa
Fontana2, Daan G. Knapen4, Crescens Tiu1, Anja Williams2, Derk Jan A de Groot4, Ulug …
Fontana2, Daan G. Knapen4, Crescens Tiu1, Anja Williams2, Derk Jan A de Groot4, Ulug …
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment …
…, SF Oosting, M Jalving, AH de Heij, DG Knapen… - …, 2024 - academic.oup.com
OBJECTIVES To compare clinical characteristics, imaging findings and treatment requirements
of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR…
of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR…
LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy
…, HK Cheung, H Jalving, SF Oosting, DG Knapen… - Cancer Research, 2023 - AACR
Background Immune checkpoint inhibitors (ICIs) can induce durable responses in multiple
different tumor types. Lymphocyte activation gene-3 (LAG-3) is one of the immune …
different tumor types. Lymphocyte activation gene-3 (LAG-3) is one of the immune …
[HTML][HTML] Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?
DG Knapen, DJA de Groot, TC Kwee… - Cancer Treatment …, 2020 - Elsevier
Immune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced
cancers, and results in increasing numbers of long-term survivors. For registration studies, …
cancers, and results in increasing numbers of long-term survivors. For registration studies, …